Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.72 USD | +1.98% | -2.89% | +56.91% |
May. 14 | Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 240.6 | 109.2 | 238.4 | - | - |
Enterprise Value (EV) 1 | 112.8 | 109.2 | 238.4 | 238.4 | 238.4 |
P/E ratio | -1.52 x | -1.8 x | -3.12 x | -2.81 x | -2.7 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | 236 x | 11.5 x |
EV / Revenue | - | - | - | 236 x | 11.5 x |
EV / EBITDA | - | - | - | - | - |
EV / FCF | -7.45 x | - | -3.41 x | -2.96 x | -2.21 x |
FCF Yield | -13.4% | - | -29.3% | -33.8% | -45.3% |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 20,885 | 22,194 | 30,877 | - | - |
Reference price 2 | 11.52 | 4.920 | 7.720 | 7.720 | 7.720 |
Announcement Date | 3/28/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | 1.009 | 20.68 |
EBITDA | - | - | - | - | - | - |
EBIT 1 | - | -32.66 | -67.1 | -80.15 | -106.7 | -114.1 |
Operating Margin | - | - | - | - | -10,570.31% | -551.83% |
Earnings before Tax (EBT) 1 | - | -31.17 | -60.39 | -77.6 | -103.2 | -112.4 |
Net income 1 | -16.24 | -31.17 | -60.39 | -77.6 | -103.2 | -112.4 |
Net margin | - | - | - | - | -10,225.45% | -543.68% |
EPS 2 | -3.780 | -7.560 | -2.740 | -2.474 | -2.747 | -2.859 |
Free Cash Flow 1 | - | -32.28 | - | -69.83 | -80.65 | -108.1 |
FCF margin | - | - | - | - | -7,991.26% | -522.8% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 8/12/22 | 3/28/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -9.575 | -9.945 | -14.39 | -15.52 | -16.14 | -21.05 | -17.67 | -20.35 | -20.65 | -21.07 | -23.5 | -24 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -9.198 | -8.929 | -12.76 | -13.91 | -14.47 | -19.25 | -16.49 | -20.21 | -21.07 | -21.84 | -23.5 | -24 |
Net income 1 | -9.198 | -8.929 | -12.76 | -13.91 | -14.47 | -19.25 | -16.49 | -20.21 | -21.07 | -21.84 | -23.5 | -24 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -5.170 | -0.8000 | -0.5800 | -0.6300 | -0.6600 | -0.8700 | -0.7300 | -0.5914 | -0.5600 | -0.5614 | -0.6400 | -0.6650 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 12/15/22 | 3/28/23 | 5/9/23 | 8/11/23 | 11/9/23 | 3/28/24 | 5/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | 128 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | - | -32.3 | - | -69.8 | -80.6 | -108 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | - | 2.17 | - | 1.39 | 0.98 | 1.12 |
Capex / Sales | - | - | - | - | 96.66% | 5.43% |
Announcement Date | 8/12/22 | 3/28/23 | 3/28/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.91% | 234M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- ACRV Stock
- Financials Acrivon Therapeutics, Inc.